Ribo Life Science Submits European Clinical Trial Application
Suzhou Ribo Life Science has submitted a clinical trial application in Europe for its novel RNAi therapeutic, RBD3133. The submission initiates a Phase 1 study.
Suzhou Ribo Life Science and its subsidiary Ribocure Pharmaceuticals AB have submitted a Clinical Trial Application (CTA) to European authorities for their novel RNAi therapeutic, RBD3133.
The drug candidate is being developed for the treatment of transthyretin amyloidosis, including conditions like familial amyloid polyneuropathy (FAP) and familial amyloid cardiomyopathy (FAC). RBD3133 targets the liver-specific protein INHBE, which is implicated in the formation of amyloid deposits.
The planned Phase 1 study will evaluate the safety, tolerability, and pharmacokinetics of RBD3133 in healthy volunteers at a European clinical research site. This submission marks a significant step forward in the company's drug development pipeline.
Ribo Life Science utilizes RNA interference (RNAi) technology, which allows for the targeted silencing of specific genes, aiming to provide new therapeutic options for various diseases.